GH icon

Guardant Health

44.47 USD
-1.62
3.51%
At close Feb 7, 4:00 PM EST
After hours
44.47
+0.00
0.00%
1 day
-3.51%
5 days
-0.09%
1 month
23.02%
3 months
55.54%
6 months
30.95%
Year to date
39.97%
1 year
101.40%
5 years
-43.34%
10 years
38.11%
 

About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Employees: 1,779

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

27% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 74

4.64% more ownership

Funds ownership: 98.16% [Q2] → 102.8% (+4.64%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

5% less funds holding

Funds holding: 280 [Q2] → 265 (-15) [Q3]

16% less capital invested

Capital invested by funds: $3.39B [Q2] → $2.84B (-$553M) [Q3]

20% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 54

62% less call options, than puts

Call options by funds: $21.3M | Put options by funds: $56M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$49
10%
upside
Avg. target
$55
23%
upside
High target
$60
35%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Goldman Sachs
Matthew Sykes
56% 1-year accuracy
22 / 39 met price target
10%upside
$49
Buy
Maintained
28 Jan 2025
Barclays
Luke Sergott
28% 1-year accuracy
13 / 46 met price target
35%upside
$60
Overweight
Initiated
23 Jan 2025

Financial journalist opinion

Based on 12 articles about GH published over the past 30 days

Neutral
Business Wire
3 days ago
Guardant Health Announces Debt Exchange Transactions
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its outstanding 0% Convertible Senior Notes due 2027 (the “2027 Notes”), pursuant to which the Company will issue $600 million aggregate principal amount of 1.25% Convertible Senior Notes due 2031 (the “New Notes”) in exchange for the ret.
Guardant Health Announces Debt Exchange Transactions
Negative
Zacks Investment Research
3 days ago
Are Medical Stocks Lagging Guardant Health (GH) This Year?
Here is how Guardant Health (GH) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Guardant Health (GH) This Year?
Neutral
Business Wire
1 week ago
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com.
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Neutral
Business Wire
1 week ago
Guardant Health's Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi Public Health Center (ADPHC) to introduce a non-invasive blood-based screening program for colorectal cancer using Guardant's Shield™ test. The agreement was set up through Hikma Pharmaceuticals PLC, a multinational pharmaceutical group and regional partner for Guardant in the Middle East and North Africa, and will be administered by the M.
Guardant Health's Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
Positive
Zacks Investment Research
1 week ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Neutral
Business Wire
2 weeks ago
Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing the benefits of Guardant's precision oncology tools across cancer screening, recurrence monitoring, treatment selection and therapy development at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, January 23-25, 2025. Key focus areas in Guardant'.
Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
Positive
Benzinga
2 weeks ago
Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test
On Tuesday, Guardant Health, Inc. GH announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy.
Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test
Positive
Investors Business Daily
2 weeks ago
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test. The post Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone appeared first on Investor's Business Daily.
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
Neutral
Business Wire
2 weeks ago
Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy. Guardant Reveal, which runs on Guardant's Smart Liquid Biopsy platform, is a blood test that.
Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients
Neutral
Business Wire
3 weeks ago
Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
PALO ALTO, Calif., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration agreement that allows biopharmaceutical companies to access the first multi-modal real-world data (RWD) that integrates comprehensive patient electronic medical record (EMR) data with both genomic and epigenomic tumor profiling information across.
Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
Charts implemented using Lightweight Charts™